Codexis, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDXS research report →
About the company
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening.
- CEO
- Alison Moore
- IPO
- 2010
- Employees
- 188
- HQ
- Redwood City, CA, US
Price Chart
- Market Cap
- $224.51M
- P/E
- -6.75
- P/S
- 2.88
- P/B
- 5.19
- EV/EBITDA
- -11.81
- Div Yield
- 0.00%
- Gross Margin
- 83.94%
- Op Margin
- -33.15%
- Net Margin
- -40.96%
- ROE
- -68.09%
- ROIC
- -21.97%
- Revenue
- $70.39M · 18.61%
- Net Income
- $-43,974,000 · 32.63%
- EPS
- $-0.50 · 43.82%
- Op Income
- $-38,332,000
- FCF YoY
- 55.60%
- 52W High
- $3.87
- 52W Low
- $0.96
- 50D MA
- $2.55
- 200D MA
- $2.02
- Beta
- 2.50
- Avg Volume
- 1.14M
Get TickerSpark's AI analysis on CDXS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | PARKER H STEWART | other | 66,350 |
| Jun 17, 26 | Collins Cynthia | other | 66,350 |
| Jun 17, 26 | Richards Christos | other | 66,350 |
| Jun 17, 26 | Smith David V | other | 66,350 |
| Jun 17, 26 | Singhvi Rahul | other | 66,350 |
| Jun 17, 26 | Martinborough Esther | other | 66,350 |
| Jun 17, 26 | DILLY STEPHEN GEORGE | other | 66,350 |
| Jun 17, 26 | De Vre Raymond | other | 66,350 |
| Jun 11, 26 | De Vre Raymond | sell | 2,605 |
| Feb 23, 26 | Lutz Stefan | other | 316,100 |
Our CDXS coverage
Recent articles, reports, and earnings notes.
No research on CDXS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CDXS report →Similar companies
Peers in the same neighborhood.